| Chugai Pharma renal anemia drug recieves Japanese approval - Pharmaceutical Business Review |
|
|
Pharmaceutical Business Review It has a longer serum half-life than other available ESAs such as Epogin Injection, enabling it to maintain hemoglobin levels targeted under the guideline for treatment of renal anemia with once-every-four-week intravenous or subcutaneous dosing. |